Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Willem J Remme

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Expert Review of Cardiovascular Therapy|November 27, 2007
Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trialRoberto Ferrari, Michel E Bertrand, Willem J Remme, et al.
European Heart Journal|April 30, 2005
The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudyCaroline A Daly, Kim M Fox, Willem J Remme, et al.
European Heart Journal|May 2, 2009
Effects of perindopril on cardiac remodelling and prognostic value of pre-discharge quantitative echocardiographic parameters in elderly patients after acute myocardial infarction: the PREAMI echo sub-studyGian Luigi Nicolosi, Sorin Golcea, Claudio Ceconi, et al.
Cardiovascular Drugs and Therapy|April 30, 2004
The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)Willem J Remme, Guenter Riegger, Per Hildebrandt, et al.
European Heart Journal|February 25, 2006
Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of riskJaap W Deckers, Dick M Goedhart, Eric Boersma, et al.
Journal of the American College of Cardiology|November 27, 2007
The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trialJasper J Brugts, Eric Boersma, Michel Chonchol, et al.
Heart (British Cardiac Society)|December 1, 2006
Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA studyAndrew Briggs, Borislava Mihaylova, Mark Sculpher, et al.
European Heart Journal|April 7, 2009
The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trialsJasper J Brugts, Toshiharu Ninomiya, Eric Boersma, et al.
European Journal of Heart Failure|May 30, 2002
Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMETPhilip A Poole-Wilson, John G F Cleland, Andrea Di Lenarda, et al.
European Journal of Heart Failure|June 9, 2004
Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN)Michel Komajda, Beatrix Lutiger, Hugo Madeira, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Expert Review of Cardiovascular Therapy|November 27, 2007
Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trialRoberto Ferrari, Michel E Bertrand, Willem J Remme, et al.
European Heart Journal|April 30, 2005
The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudyCaroline A Daly, Kim M Fox, Willem J Remme, et al.
European Heart Journal|May 2, 2009
Effects of perindopril on cardiac remodelling and prognostic value of pre-discharge quantitative echocardiographic parameters in elderly patients after acute myocardial infarction: the PREAMI echo sub-studyGian Luigi Nicolosi, Sorin Golcea, Claudio Ceconi, et al.
Cardiovascular Drugs and Therapy|April 30, 2004
The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)Willem J Remme, Guenter Riegger, Per Hildebrandt, et al.
European Heart Journal|February 25, 2006
Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of riskJaap W Deckers, Dick M Goedhart, Eric Boersma, et al.
Journal of the American College of Cardiology|November 27, 2007
The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trialJasper J Brugts, Eric Boersma, Michel Chonchol, et al.
Heart (British Cardiac Society)|December 1, 2006
Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA studyAndrew Briggs, Borislava Mihaylova, Mark Sculpher, et al.
European Heart Journal|April 7, 2009
The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trialsJasper J Brugts, Toshiharu Ninomiya, Eric Boersma, et al.
European Journal of Heart Failure|May 30, 2002
Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMETPhilip A Poole-Wilson, John G F Cleland, Andrea Di Lenarda, et al.
European Journal of Heart Failure|June 9, 2004
Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN)Michel Komajda, Beatrix Lutiger, Hugo Madeira, et al.
Pageof 4